G-CSF use should be avoided during periods when a patient is at risk of CRS [44], due to the overlapping symptomology of febrile neutropenia and CRS, and the release of cytokines with G-CSF treatment (level IIB) [44]. The gene discussed is CSF3; the disease is congenital rubella syndrome.